Blood glucose monitor problems to be discussed at March 20-21 FDA panel meeting.
This article was originally published in The Tan Sheet
Executive Summary
BLOOD GLUCOSE MONITOR PROBLEMS SLATED FOR PANEL DISCUSSION at a March 20-21 meeting of FDA's Clinical Chemistry & Clinical Toxicology Devices Panel, according to an upcoming Federal Register notice. FDA is looking for input from the advisory panel and from public presentations by professional organizations, industry and consumers on "mechanisms to help minimize problems associated with" self-monitoring blood glucose systems. The meeting is scheduled to take place at the Holiday Inn in Gaithersburg, Md.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning